Abstract Biomedical innovation and translation are increasingly emphasizing research using Bbig data.T he hope is that big data methods will both speed up research and make its results more applicable to Brealworld^patients and health services. While big data research has been embraced by scientists, politicians, industry, and the public, numerous ethical, organizational, and technical/methodological concerns have also been raised. With respect to technical and methodological concerns, there is a view that these will be resolved through sophisticated information technologies, predictive algorithms, and data analysis techniques. While such advances will likely go some way towards resolving technical and methodological issues, we believe that the epistemological issues raised by big data research have important ethical implications and raise questions about the very possibility of big data research achieving its goals.
Box 1 Sources of big data for use in biomedicine • Public health data (e.g. health department databases)
• Patient-generated health data
• Personal health and health-related activity monitoring tools (mobile health) • Health-related websites e.g. patientslikeme.com
• Non-health data (but relevant to health)
• Credit card/phone/internet activity data
• Census, death, police records
• Employee sick days
• Social media (Facebook, Twitter, blogs etc)
• Other internet resources and internet searches (e.g. on 'flu)
In the laboratory, big data research may entail the sequencing of genomes (which contain 3 billion bases and tens of millions of genetic variants) and subsequent aggregation of genomic data to identify clinically relevant biomarkers, with the ultimate aim of generating a personalized predictive Bdata cloud^for each patient (Waldman and Terzic 2016; Roden and Denny 2016; Vicini et al. 2016) . Other -omics platforms may also be incorporated, such as transcriptome, proteome, metabolome data, etcetera (Mischak et al. 2015; Tzoulaki et al. 2014; Nair et al. 2014) . Big data can also be used in the laboratory to screen for new drugs, indications and combinations, and for biomarkers that predict their safety and efficacy in individual patients (Roden and Denny 2016; Chen and Butte 2016) .
While epidemiological data used in public health research have always had the potential of reaching Bbigd imensions, the relative scale of information has been expanding. For example, big data from electronic health records enable the building of predictive models using larger sample sizes and a larger number of variables than what was feasible in the past (Goldstein et al. 2016) . And new sources of big data allow public health researchers to collect, link, and analyse enormous amounts of exposure and behavioural data from, for example, mobile health applications, social media, and credit card, phone, or internet activity data (Vayena et al. 2015; Swan 2013) .
Big data research also offers new approaches to assessing the safety, effectiveness, and costs of health technologies and health services. It may do this by supporting traditional randomized clinical trials, for example by assisting with recruitment or identification of patients with particular biomarkers (Raghupathi and Raghupathi 2014; Vicini et al. 2016) . Big data research may also supplement or replace traditional trials with Breal world^comparative effectiveness studies or other observational research using linked electronic health records, insurance claims data, pharmacy dispensing data, and so on (Bate et al. 2016; Oye et al. 2015; Sacristán and Dilla 2015; Hemkens, ContopoulosIoannidis, and Ioannidis. 2016a, b, c) .
Support For Big Data Biomedical Research
Many clinicians and biomedical researchers see enormous value in big data research, which has been touted as the route to (among other things) data-driven medicine, translational medicine, personalized medicine, precision medicine, patient-centred care, learning healthcare systems, and value-based and accountable care (e.g. Shah and Tenenbaum 2012; Alyass, Turcotte, and Meyre 2015; Angus 2015; Chawla and Davis 2013; Roski, Bo-Linn, and Andrews 2014; Raghupathi and Raghupathi 2014; Collins and Varmus 2015) . Indeed, the argument is frequently made by clinicians and researchers that big data research will Btransform^and Brevolutionize^healthcare as we know it (e.g. Adams 2015; Parikh, Kakad, and Bates 2016; Murdoch and Detsky 2013; Hood and Auffray 2013) .
Big data research has also been embraced by politicians and those responsible for public health systems. In the United States, for example, Barack Obama launched a BBig Data Research and Development Initiative^in 2012 (Office of Science and Technology Policy 2012) and big data is an explicit part of the vision of the National Academy of Medicine (Larson 2013; Dzau and Ginsburg 2016) . Big data also underlie much of the Precision Medicine Initiative (Collins and Varmus 2015) . The idea of big data has been similarly embraced by (among others) the U.K. National Health Service, the European Union, and the Chinese government (e.g. NHS England 2016; Auffray et al. 2016; China Daily USA 2016) . In some settings, this is part of a broader move towards increasing transparency and public accountability in government (e.g. data.gov.uk 2016; data.gov 2016) . Big data research is also drawing the attention of pharmaceutical and biotechnology companies, as well as private health insurers and health service providers (e.g. McKinsey and Company 2013; Fierce Biotech 2016; Financial Review 2016) .
Given this excitement, big data biomedical research is unsurprisingly supported by an ever-growing array of nationally and globally linked biobanks and databases (e.g. Genomics England 2016 (Aboab et al. 2016; Bourzac 2015) . The scientific, political, and commercial interest in big data research has, in turn, generated considerable public interest in big data, as evident in the growth of patient-initiated research networks (e. 
Concerns About Big Data Research in Healthcare
The degree of scientific, medical, political, and commercial commitment to big data biomedical research might give the impression that its processes and systems were well-established and morally, politically, and economically clear-cut, sustainable, and non-problematic. This is not, however, the case, and numerous concerns have been raised about big data research. Broadly speaking, these can be divided into 1) traditional research ethics concerns; 2) social and organizational concerns; and 3) technical and methodological concerns.
BTraditional^Research Ethics Concerns
In existing bioethical scholarship, the challenges of big data are most commonly framed as reflecting the need to balance individual research participant rights against the common good; and principles such as individual autonomy and respect for persons against potentially competing principles such as altruism and solidarity (e.g. Vayena et al. 2015; Larson 2013; Docherty 2014; Ploug and Holm 2015) . More specifically, extensive attention is paid to the issues of consent, privacy, data sharing, return of results, benefit sharing, ownership, trust, and custodianship.
Consent
Those with concerns about consent to big data biomedical research emphasize the challenges of obtaining consent from large numbers of research participants across a large number of institutions within a large number of regulatory jurisdictions (e.g. Zarate et al. 2016; Christen et al. 2016) . Informed consent is complicated by the fact that data are often collected for unspecified future research purposes, thus making it necessary to consider whether consent can be Bopen ended^or whether participants need to have more control (e.g. Zarate et al. 2016; Frizzo-Barker et al. 2016) ; by the fact that data are often collected for non-research (e.g. clinical or administrative) or even non-medical (e.g. social media) purposes (e.g. Zarate et al. 2016 ; Ploug and Holm 2015) using a wide variety of more or less consistent and adequate consent mechanisms (e.g. Chow-White et al. 2015) ; and by the fact that there is an increasingly blurred line between Bresearch^and Bnonresearch^uses of data and between data that is identifiable and data that is anonymous and thus legally exempt from many existing consent requirements (e.g. Zarate et al. 2016; Terry 2012; Mostert et al. 2015; Ioannidis 2013) . A common theme in discussions of consent to big data research is that there is an urgent need for new models of consent that are better suited to big data such as Bopen consent,^Bmeta consent,^and Bportable legal consent^(e.g. Zarate et al. 2016; Terry 2012; Docherty 2014; Ploug and Holm 2015; Schadt 2012 ).
Confidentiality and Privacy
The size, complexity, dispersion, linkage, long-term storage, automaticity, globalization, and commercialization of big data are all seen to both amplify the need to protect confidentiality and add complexity to efforts to do so. The heterogeneity and networking of big data and global moves towards Bopen data^blur conceptual distinctions such as those between health-related data and non-health-related data, between personal and nonpersonal data, between individual and group-level privacy, and between Bprimary^and Bsecondary^uses of data-distinctions that often form the basis of existing confidentiality (and consent) rules (e.g. Terry 2013; Hoffman 2010 Hoffman , 2014 Hoffman , 2016 Schadt 2012; Frizzo-Barker et al. 2016; Erdmann 2013; ChowWhite et al. 2015; Stoeklé et al. 2016; Shoenbill et al. 2014) . Furthermore, big data analytics have reached a level of sophistication that makes it impossible to promise perfect anonymity, even if all identifiers are removed from a particular segment of data (e.g. Schadt 2012 ). There is a rapidly growing literature on finding optimal methods for de-identification; this literature largely shows that there is always a risk of re-identification and while this risk can be minimized, the minimization process may require loss of a lot of valuable information (Scaiano et al. 2016; Prasser, Kohlmayer, and Kuhn 2016a; b; Moore et al. 2015; Zuccon et al. 2014; Gal et al. 2014) . Moreover, even if individuals cannot be reidentified (e.g. if data are sufficiently aggregated), there is still the potential for group-level harm in the form of profiling, discrimination, and loss of trust in medicine (e.g. Kaplan 2016; Hoffman 2014 Hoffman , 2016 Zarate et al. 2016 ).
Return of Results and Incidental Findings
Often in the course of biomedical research, information comes to light that is not directly related to the research question being asked but might have clinical significance for the research participant. The dilemma here is that, while informing participants of such findings might enable them to prevent or respond more rapidly to disease, the clinical significance of findings is not always obvious; research laboratories are not subject to the same quality control as are clinical laboratories (so findings may not be accurate); and people might not want to receive such information no matter how clinically Bsignificant^it might be. This dilemma is magnified by big data research, which is far more likely to generate incidental findings simply by virtue of its scale. The issue is also made more complex by questions about the validity, reliability, and utility of the results of big data research (e.g. Fischer et al. 2016; Shoenbill et al. 2014) . For example, the majority of the information on genomic variants may be of unknown clinical value and may mislead clinicians and patients as to its pathogenic potential (Manrai, Ioannidis, and Kohane 2016) .
Data Sharing, Control and Custodianship
In any kind of research that involves the long-term storage and repeated use of personal data (and/or tissue), issues arise as to who should have access to the materials and what kinds of Bsecondary uses^are acceptable (including as part of commercial and international collaborations) (e.g. Larson 2013; Dove et al. 2016; Kaplan 2016) . In the context of Bbig data^research, these issues are magnified by the scale of the data and the potential for data to be shared and used for myriad purposes.
A related issue is uncertainty regarding the degree and kinds of personal control that people should have over their data. One way in which this issue has manifested itself in the big data context is in growing efforts to find ways to erase and forget big data once it is deemed that their future value and/or risks to participants are such that forgetting them may be the best option (Newman 2015) . For example, software like Oblivion may be used to implement the Bright to be forgotten^of individuals in Google searches (Advisory Council to Google on the Right to be Forgotten 2015; Motherboard 2015) . No matter how sophisticated mechanisms become for placing control in participants' hands, however, some decisions will inevitably need to be made on their behalf. This has brought to the fore the importance of appropriate custodianship of big data, which can be particularly challenging when research is Bglobal^and takes place in multiple (public and private, health and non-health) sectors, as is the case with big data research (e.g. Carter, Laurie, and Dixon-Woods 2015; Hassey 2015; Booth 2015; Rothstein 2015; Dove, Knoppers, and Ma'n 2013, Dove et al. 2016 ).
Social and Organizational Concerns
Several authors have noted that the social organization of big data research is profoundly different to that of more traditional project-based biomedical research. Numerous associated barriers to effective big data research have been identified, including the difficulties associated with funding large, cross-jurisdiction research collaborations (Crump, Sundquist, and Winkleby 2015; Kaiser 2016 ) and the costs associated with storing, curating, accessing, and transferring data (Bourne, Lorsch, and Green 2015; Costa 2014) . Most types of big data tend to come at costs per item that are much smaller than most traditional-based research, and the cost for many big-data platforms is rapidly deflating, e.g. the cost of genotyping has decreased over 100 million-fold in the last fifteen years (Souilmi et al. 2015) . However, the volume of information for many types of big data is expanding at such an exponential pace that it easily overwhelms resources (Sboner et al. 2011) .
In part because it is so expensive, big data research has developed into a Bmixed economy,^with both public and private funding. The commercialization of big data research has raised questions about the meaning of concepts such as Bprivacy^and Bpublic interest^(e.g. Kaplan 2016; Terry 2012) ; the nature of relationships between data donors and custodians (moving away from fiduciary relationships based on trust and professionalism and towards commercial models) (e.g. Stoeklé et al. 2016) ; and the likelihood of those who participate in research, including both individual data and tissue donors and communities, benefiting from the products of the research (e.g. Vayena et al. 2015; Kaplan 2016) . Commercialization has also brought to the fore questions about whether or not people should Bown^their data and other related intellectual property (e.g. Kaplan 2016 ) and has raised concerns about the lack of incentives for (affordable) data sharing (Dickson and Pfeifer 2016; Gilbert, Goldstein, and Hemingway 2015; Oye et al. 2015; Terry 2012 Terry , 2013 .
Whether publicly or privately funded, big data research tends to take the form of Bconsortia science ( Mason, Lipworth, and Kerridge 2016) . While this model of science has major advantages e.g. allowing for coordinated research methods, data sharing, and peer review and, ideally, a marked reduction in selective reporting bias (Burgio et al. 2013) , it also poses challenges such as reduced scientific freedom, Binbreedingâ nd potential exclusion of researchers who are not part of consortia, and pressure on scientists to Bproduce^or risk losing both their funding and public credibility (e.g. Christen et al. 2016; Dove and Özdemir 2015) .
Other social and organizational barriers that have been identified include the need to bring together numerous otherwise disparate groups including basic scientists, epidemiologists, computer scientists, informaticians, statisticians, mathematicians, clinicians, regulators, insurers, and consumers (Alyass et al. 2015) and the need for patients, clinical practitioners, regulators, and payers to adapt to Blearning healthcare sys-tems^and Bsystems medicine^where data is not only Bbigger^than ever but also freely shared and generated continuously in the Breal world^rather than solely in clinical trials (Hood and Auffray 2013; Bate et al. 2016; Sacristán and Dilla 2015; Costa 2014) . Accomplishing some of these transformations may ultimately raise the overall standards for research, its reliability, and its translational applicability, and this may even be the greatest benefit from trying to work collaboratively with Bbig data.^However, reaching these standards is not easy.
Technical and Scientific Concerns
While some methods of big data research would be familiar to any biomedical researcher (e.g. defined epidemiological, economic, and clinical studies using linked biological, clinical, administrative, and behavioural datasets), other forms of big data research-such as generating a Bdata cloud^that will lead to completely personalized medicine for each individual-are still highly aspirational and ill-defined and their performance is either unknown or already documented to be problematic. Indeed, the scientific literature on big data research is replete with articles describing unresolved technical and scientific barriers to big data research, such as:
& lack of comparability of datasets between settings and over time (interoperability) and the associated difficulty in linking individuals across datasets, particularly in fragmented health systems and across jurisdictions (Janssen et al. 2014; Weber et al. 2014; Hendler 2014; Goossens et al. 2015 (Lazer et al. 2014) ; and & over-powered analyses and problems with using traditional statistical methods and rules that may lead to a flurry of false-positive results (Ioannidis 2005b; Rothwell 2005; Patel, Burford, and Ioannidis 2015, Patel et al. 2016) With respect to data analysis, big data leads many researchers to address a much larger number of questions, often without a clear hypothesis or with much lower prior odds than their top choices might have had. Thus, they are likely to operate in a space where the chances of getting false-positive, spurious results are very high (Ioannidis 2005b) . Furthermore, many of the promises of big data, such as personalized (or precision) treatment, rely on extending concepts that have largely failed or have very high error rates, e.g. subgroup analyses which have long been known to have very low validity (Rothwell 2005) . Compared with experimental designs, big data may also have lower credibility because they typically have less regulatory oversight. With huge sample sizes, traditional statistical rules applied in other types of research may make little sense, e.g. p-values of 10 -100 may still reflect false-positive results (Patel et al. 2016) . The geometric increase in analytical options in very rich datasets, such as selecting which variables to adjust for, may also increase the phenomenon of vibration of effects, where different analytical options lead to a range of different results; with added selective reporting, the published results may offer a highly distorted picture . Many fields that have been using data-rich analyses with multiple analytical options have witnessed a flurry of spurious results (Fiedler 2011) . Empirical studies are needed to understand the implications of having diverse options in the analysis of big data for the reliability of the inferences made (Ryan et al. 2012; Madigan et al. 2013 ).
Misconceptions About the Scientific Potential of Big Data Research
Many of these problems are conceptualized as technical and conceptual challenges that can be overcome by, for example, more sophisticated technologies such as data storage and cloud computing (Bender 2015; Costa 2014; Jee and Kim 2013; Bourne et al. 2015) and by more sophisticated predictive algorithms and data analysis techniques such as machine learning and optical character recognition for unstructured data (Murdoch and Detsky 2013; Waldman and Terzic 2016; Costa 2014) . While it is likely that such advances will go some of the way towards addressing technical and methodological concerns (Schneeweiss and Avorn 2005; Bohensky et al. 2010) , we believe that these issues are more fundamental-revealing epistemological misconceptions and raising questions about the very possibility of big data research achieving its goals.
In its vast majority, big data research is observational rather than experimental, even though randomized controlled trials may encompass elements of big data collection or link to big data resources-mostly for conducting secondary analyses. Crucially, despite hopes to the contrary, the deficiencies of observational studies (e.g. confounding by indication) do not get eliminated with big data, and in fact they may be compounded by the volume and often suboptimal quality of the information.
Another concern is that big data may be promoted as being able to replace experimental, randomized studies for pivotal questions, e.g. documenting treatment effectiveness, with claimed advantages being more real-life settings, representativeness, and low cost. However, these advantages may be misconceptions (Hemkens, Contopoulos-Ioannidis, and Ioannidis 2016c) . For example, many big datasets suffer from strong selection biases (e.g. referral settings) and the cost of many electronic healthcare systems being set up and continuously upgraded may be prohibitive (Joyner, Paneth, and Ioannidis 2016) .
Overall, the idea that big is necessarily better has very little epistemological support. On the one hand, traditional research has typically had a problem of being underpowered to detect modest effect sizes that would be of scientific and/or clinical interest. This has been a pervasive problem in many biomedical fields as well as in many social sciences. In theory, big data can eliminate this problem, but they create additional challenges due to their overpowered analysis settings (as described above). Moreover, minor noise due to errors or low quality information can easily be translated into false signals (Khoury and Ioannidis 2014) . Analysing rubbish or incommensurable datapoints may not yield useful inferences. The process of analysing many types of big data has even been called Bnoise discovery^ (Ioannidis 2005a) .
Ethical Implications of Epistemological Misconceptions
Misconceptions about the scientific potential of big data may have numerous normative implications, some of which have already been identified (for a useful summary of current thinking in this regard, see Mittelstadt and Floridi 2016) . The complexity of analytic models and predictive algorithms may, for example, limit the capacity for the public, and even experts, to interpret and question research findings. This can cause real harm if people act on false predictions (including, but in no way limited to those stemming from Bincidental findings^) (Fischer et al. 2016; Hoffman 2014; Dereli et al. 2014; Stoeklé et al. 2016; Hoffman and Podgurski 2013; Vayena et al. 2015) or lose sight of ethically important contextual nuances that are obscured by big data analyses (Mittelstadt and Floridi 2016; Busch 2014; Boyd and Crawford 2012) . There are also numerous problems with the view that big data is somehow Bobjective,^including that this obscures the fact that all research questions, methods, and interpretations are value-laden; makes it easier to ignore technical quality issues and biases; and, more generally, makes it easier to justify unbounded use of big data (Mittelstadt and Floridi 2016; Crawford, Gray, and Miltner 2014; Puschmann and Burgess 2014; Boyd and Crawford 2012) . Finally, other important kinds of research can be stifled if we accept the view that big data will give all the answers and that, therefore, there is no need for hypothesis or experimentation (Christen et al. 2016; Mittelstadt and Floridi 2016; Callebaut 2012; Boyd and Crawford 2012) .
A more general consequence of epistemological misconceptions about big data research is that the promises made by Bbig data scientists^might simply not eventuate and big data research will prove to be (yet another) example of over-hyped biomedical science and technology. This over-hyping cannot be blamed solely on scientists, governments, and commercial sponsors of big data research, as it may also be a consequence of (un)critical attention of bioethics and other social sciences. While this might seem like a relatively benign issue, scientific hype is a substantial moral and political problem because it can undermine the overall credibility of science among the public (Caulfield 2004) . Many applications of big data research come closer to the public than other forms of biomedical research and may even involve the public as citizen scientists collecting and using their own data cloud. While this is exciting, failures of the approach will be more readily noted by the public and may generate further mistrust. In this regard, it is noteworthy that critics, both in scientific and business settings, have begun to question whether big data is being over-hyped (e.g. Broder et al. 2015; Howard 2013; Christen et al. 2016 ) and whether governments might be guilty of exploiting big data resources and public goodwill in their race to demonstrate their commitment to economic stimulation, healthcare progress, and global health security (e.g. Terry 2012; Vayena et al. 2015; Dove and Özdemir 2015) . Of course, if big data initiatives fail to deliver on their promises, governments will also stand to lose both the trust of their citizens and the anticipated gains of biomedical innovation.
Towards a More Considered Critique of Big Data
There have recently been calls for social scientists, researchers, and research ethics committees to be more alert to the links between ethics and methodology (Mittelstadt and Floridi 2016; Vayena et al. 2015) . For example, after conducting a review of the ethics of big data, Mittelstadt and Floridi argued for Bthe importance of epistemology in assessing the ethics of big data^and for the need for Bmuch greater scrutiny^of this relationship (Mittelstadt and Floridi 2016, 303) . We agree with this sentiment and think that there is an important role for ethics, as well as public health, epidemiology, and the social and political sciences, in countering both specific epistemological misconceptions and the general scientific hype that surrounds big data. It is crucial that any normative critique of big data research is alert to organizational, technical, and epistemological challenges associated with this kind of research; and to both the strengths and limitations of new informational and computational technologies towards fully resolving these issues.
It is obvious that single oversight bodies, such as research ethics committees, cannot be solely responsible for ensuring the rigour, utility, and probity of big data. Research ethics committees do, however, undoubtedly need to evolve, both in terms of their structures and processes, in response to the emergence of big data. Research ethics committees could, for example, be more alert to questions of whether research teams and consortia have appropriate expertise and capacity for systematic review, publication oversight, and coordination (Christen et al. 2016; Vayena et al. 2015) . Research ethics committees could also be encouraged and provided with the resources to Bhold researchers accountable for meeting technical standards that make data usable when it is shared^since it is often the social benefits associated with big data that Bmotivate participants to risk their privacy^ (Vayena et al. 2015, 44) . Finally, research ethics committees could also demand the preregistration of ideas, protocols, and analyses to reduce selective reporting bias (Hemkens, ContopoulosIoannidis, and Ioannidis 2016c) and require that investigators explicitly describe their analyses as exploratory (and thus requiring further validation) when such preregistration has not occurred.
Because epistemology and ethics are so tightly linked in relation to big data, it is also the responsibility of scientists, research sponsors, and peer reviewers to consider the complex epistemological issues raised by big data, including by ensuring that (adapted from (Hemkens, Contopoulos-Ioannidis, and Ioannidis 2016c) 
):
& any research is preceded by a systematic review of existing evidence to ensure that the research outcomes are likely to be novel and useful; & Bbig data^approaches are, in fact the best methods to answer particular research questions (e.g. because they are difficult or impossible to address using other methods); & methods are sound-e.g. there is clarity regarding the distinction between a priori and exploratory (post hoc) analyses and detailed planning of all aspects of the former; & results are interpreted in the context of all available evidence; & datasets and studies are pre-registered (whenever appropriate) to ensure non-duplication, discourage reporting bias; and promote data sharing and validation; and & organizational systems are in place to promote data sharing and joint analyses and useful re-analyses.
Scientists, research sponsors, and peer reviewers may also have important insights to offer research ethics committees, which help guide their deliberations. For example, they could inform and guide ethics committees about the need to consider selection and other biases in their considerations regarding consent; the likelihood of re-identification; and the ethical compromises that might be required in order to promote data sharing.
Conclusion
Big data research has the potential to dramatically increase the efficiency and impact of biomedical research. But big data also has the potential to be substantially disruptive, not simply because of the ways that it could shape medicine but also because it requires that knowledge and science are transparent, accessible, and widely shared. And like other large scientific Bprojects,^such as the human genome project, big data research holds enormous commercial appeal and so has attracted the interest of both the public and private sector. The challenge for both proponents and critics of big data is to have an appreciation of the enormous complexity of big data-including the ethical implications of technical and methodological challenges-so that they can avoid both hype and moral panic.
